Agreements - Lilly (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Feb. 28, 2022	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Collaborative Agreements disclosures
Aggregate amount of transaction price allocated to remaining performance obligations		$ 70,100
Revenue from contract with customer		38,078	$ 15,706
Amount of obligation included in long-term deferred revenue		46,694		$ 47,717
License and milestone fees
Collaborative Agreements disclosures
Revenue from contract with customer		30,892	$ 157
Lilly
Collaborative Agreements disclosures
License agreement upfront payment receivable	$ 13,000
License agreement additional payment receivable	$ 32,500
License agreement additional target term	4 years
License agreement, target selection fees and development, regulatory and commercial milestone payments receivable	$ 1,700,000
Aggregate amount of transaction price allocated to remaining performance obligations	13,000
Lilly | Upfront payment
Collaborative Agreements disclosures
Estimated payments to received	13,000
Lilly | License and milestone fees
Collaborative Agreements disclosures
Revenue from contract with customer		9,200
Lilly | Initial targets
Collaborative Agreements disclosures
Revenue from contract with customer	9,200	9,200
Lilly | Material rights to obtain licenses to replacement targets
Collaborative Agreements disclosures
Revenue from contract with customer	$ 3,800
Amount of obligation included in long-term deferred revenue		$ 3,800